[1] KHATKAR H, SEE A. Stem Cell Therapy in the Management of Fracture Non-Union - Evaluating Cellular Mechanisms and Clinical Progress. Cureus. 2021;13(3):e13869.
[2] 刘璠,祁俊.骨折不愈合与延迟愈合的成因与治疗[J].中华创伤骨科杂志, 2005,7(5):405-408.
[3] 刘金伟,陈允震,万春友.应力作用下骨不连断端组织中成骨因子的变化[J].中国组织工程研究,2021,25(23):3619-3624.
[4] KASTIRR I, REICHARDT M, ANDRESEN R, et al. Therapy of aseptic nonunions with parathyroid hormone. Eur J Orthop Surg Traumatol. 2019;29(1):169-173.
[5] ANDERSEN C, WRAGG NM, SHARIATZADEH M, et al. The Use of Platelet-Rich Plasma (PRP) for the Management of Non-union Fractures. Curr Osteoporos Rep. 2021;19(1):1-14.
[6] SCHMAL H, BRIX M, BUE M, et al. Nonunion - consensus from the 4th annual meeting of the Danish Orthopaedic Trauma Society. EFORT Open Rev. 2020;5(1): 46-57.
[7] MARCK RE, GARDIEN K, VLIG M, et al. Growth Factor Quantification of Platelet-Rich Plasma in Burn Patients Compared to Matched Healthy Volunteers. Int J Mol Sci. 2019;20(2):288.
[8] MIDDLETON KK, BARRO V, MULLER B, et al. Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries. Iowa Orthop J. 2012;32:150-163.
[9] ALSOUSOU J, THOMPSON M, HULLEY P, et al. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br. 2009;91(8):987-996.
[10] ALVES R, GRIMALT R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018;4(1):18-24.
[11] HALPERN BC, CHAUDHURY S, RODEO SA. The role of platelet-rich plasma in inducing musculoskeletal tissue healing. HSS J. 2012;8(2):137-145.
[12] RODRIGUEZ-MERCHAN EC, FORRIOL F. Nonunion: general principles and experimental data. Clin Orthop Relat Res. 2004;(419):4-12.
[13] EINHORN TA, GERSTENFELD LC. Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015;11(1):45-54.
[14] FISHER JS, KAZAM J J, FUFA D, et al. Radiologic evaluation of fracture healing. Skeletal Radiol. 2019;48(3):349-361.
[15] 姜苗苗,谭勇海,金鑫,等.富血小板血浆联合体外冲击波治疗骨不连的临床研究[J].中医正骨,2020,32(2):30-35.
[16] MEDDA S, SNOAP T, CARROLL EA. Treatment of Young Femoral Neck Fractures. J Orthop Trauma. 2019;33 Suppl 1:S1-S6.
[17] MILGRAM JW. Nonunion and pseudarthrosis of fracture healing. A histopathologic study of 95 human specimens. Clin Orthop Relat Res. 1991;(268):203-213.
[18] HAUGSTVEDT JR, WONG CW. Arthroscopic treatment for nonunion of the scaphoid. Handchir Mikrochir Plast Chir. 2020;52(5):413-418.
[19] LAMMENS J, VAN LAER M, MOTMANS R. Ilizarov treatment for femoral mal-union or non-union associated with fatigue fracture of an intramedullary nail. Injury. 2008;39(2):256-259.
[20] KURKLU M, YURTTAS Y, KOSE O, et al. Adjunctive hyperbaric oxygen therapy in the treatment of atrophic tibial nonunion with Ilizarov external fixator: a radiographic and scintigraphic study in rabbits. Acta Orthop Traumatol Turc. 2012;46(2):126-131.
[21] HANNEMANN PF, MOMMERS EH, SCHOTS JP, et al. The effects of low-intensity pulsed ultrasound and pulsed electromagnetic fields bone growth stimulation in acute fractures: a systematic review and meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 2014;134(8):1093-1106.
[22] PADILLA F, PUTS R, VICO L, et al. Stimulation of bone repair with ultrasound: a review of the possible mechanic effects. Ultrasonics. 2014;54(5):1125-1145.
[23] BOTTEGONI C, DEI GL, SALVEMINI S, et al. Homologous platelet-rich plasma for the treatment of knee osteoarthritis in selected elderly patients: an open-label, uncontrolled, pilot study. Ther Adv Musculoskelet Dis. 2016;8(2):35-41.
[24] DALLARI D, STAGNI C, RANI N, et al. Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study. Am J Sports Med. 2016;44(3): 664-671.
[25] KANCHANATAWAN W, ARIRACHAKARAN A, CHAIJENKIJ K, et al. Short-term outcomes of platelet-rich plasma injection for treatment of osteoarthritis of the knee. Knee Surg Sports Traumatol Arthrosc. 2016;24(5):1665-1677.
[26] KASTIRR I, REICHARDT M, ANDRESEN R, et al. Therapy of aseptic nonunions with parathyroid hormone. Eur J Orthop Surg Traumatol. 2019;29(1):169-173.
[27] FAN T, HUANG G, WU W, et al. Combined treatment with extracorporeal shock-wave therapy and bone marrow mesenchymal stem cell transplantation improves bone repair in a rabbit model of bone nonunion. Mol Med Rep. 2018;18(4):4156.
[28] ZHANG L, JIAO G, REN S, et al. Exosomes from bone marrow mesenchymal stem cells enhance fracture healing through the promotion of osteogenesis and angiogenesis in a rat model of nonunion. Stem Cell Res Ther. 2020;11(1):38.
[29] LOPEZ S, VILAR JM, SOPENA JJ, et al. Assessment of the Efficacy of Platelet-Rich Plasma in the Treatment of Traumatic Canine Fractures. Int J Mol Sci. 2019; 20(5):1075.
[30] XU PC, XUAN M, CHENG B. Effects and mechanism of platelet-rich plasma on military drill injury: a review. Mil Med Res. 2020;7(1):56.
[31] CHU W. Treatment of nonunion with autologous bone transplantation combined with platelet-rich plasma and extracorporeal shock wave. Zhongguo Gu Shang. 2019;32(5):434-439.
[32] ANDERSEN C, WRAGG NM, SHARIATZADEH M, et al. The Use of Platelet-Rich Plasma (PRP) for the Management of Non-union Fractures. Curr Osteoporos Rep. 2021;19(1):1-14.
[33] LYNCH MD, BASHIR S. Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature. J Dermatolog Treat. 2016;27(3):285-289.
[34] YU W, JINGXIN Z, LINGWEI K, et al. Involvement of bone-specific alkaline phosphatase and procollagen I carboxy-terminal propeptide as predictors of early fracture risk in Chinese Children with juvenile osteoporosis: An interventional clinical trial. Bangl J Pharmacol. 2018;13(2):164.
[35] URAKAWA H, ANDO Y, HASE T, et al. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study. Int J Cancer. 2020;146(12): 3504-3515.
[36] VALLET S, HOYLE NR, KYLE RA, et al. A role for bone turnover markers beta-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leuk Lymphoma. 2018;59(10):2431-2438.
|